EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Comprehensive analysis of exosome-related gene signature in multiple myeloma prognosis and immune microenvironment evaluation

Dong Zheng, Bingxin Zhang, Quanqiang Wang, Sisi Zheng, Yibo Xia, Ziwei Zheng, Zhili Lin, Shuxia Zhu, Xinyi Zhang, Luning Cui, Hansen Ying, Tianyu Zhang und 14 weitere

Cancer Immunology, Immunotherapy · 2025

DOI: 10.1007/s00262-025-04097-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Dong Zheng und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, Zhejiang, China. Hauptthemen laut MEDLINE: Multiple Myeloma, Tumor Microenvironment, Exosomes, Biomarkers, Tumor. Die Arbeit nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Wenzhou Municipal Science and Technology Bureau, Discipline Cluster of Oncology, Wenzhou Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple myeloma (MM) is a genetically complicated plasma cell malignancy characterized by malignant plasma cell proliferation and monoclonal immunoglobulin synthesis. As a disease that remains incurable, enhancing prognostic accuracy is of paramount importance. Tumor-derived exosomes (TDEs) play key roles in modulating the tumor microenvironment, angiogenesis and immune system. Exosomes are involved in multiple processes contributing to cancer progression, including in MM. However, the connection between myeloma and exosome-related genes (ERGs) has not been explored. Therefore, we aim to establish a more accurate model to evaluate the prognosis of MM patients based on the exosome-related genes. This study established an ERG-based prognostic model for MM and investigated its association with the immune microenvironment. Using transcriptomic data from GSE136337 (training set) and GSE24080 (validation set), we identified six prognostic ERGs (BIRC5, LDHA, MRPS30, MRPL15, RPL26L1, and S1PR2) through Cox and LASSO regression analyses, constructing a risk-scoring model. The model demonstrated robust predictive performance for 3-year survival (AUC = 0.74 in training set; AUC = 0.69 in both validation sets). A nomogram integrating age, ISS stage, and risk score significantly improved prognostic accuracy (3-year survival AUC = 0.77). Functional enrichment analysis revealed that high-risk patients exhibited activation of oncogenic pathways, including cell cycle regulation and DNA replication (P < 0.01). Immune profiling identified an immunosuppressive microenvironment in the high-risk group, characterized by reduced CD8 + T cell infiltration (P = 0.004) and elevated TIDE scores (P = 0.012), indicating increased resistance to immunotherapy. TCGA database validation and in vitro experiments confirmed the critical role of these ERGs in tumor microenvironment remodeling. To our knowledge, this represents the first ERG-based prognostic system for MM, providing a biologically insightful and clinically applicable tool for personalized treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaTumor MicroenvironmentExosomesBiomarkers, TumorTranscriptomeHumansPrognosisGene Expression ProfilingNomogramsFemaleMaleGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

ExosomeImmune microenvironmentMultiple myelomaPrognosis

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, Zhejiang, China.
  • Department of Medical Laboratory Technology, School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, 325000, Zhejiang Province, China.
  • Department of Hepatobiliary Surgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, 325000, Zhejiang, China.
  • Department of Blood Transfusion, The First Hospital, Wenzhou Medical College, Wenzhou, 325000, Zhejiang Province, China.
  • Department of Hepatobiliary Surgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, 325000, Zhejiang, China. wzjinzx@163.com.
  • Department of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, Zhejiang, China. jiangsongfu@189.cn.

Förderung

  • National Natural Science Foundation of China
  • Wenzhou Municipal Science and Technology Bureau
  • Discipline Cluster of Oncology, Wenzhou Medical University

Zitieren

APA

Zheng, D., Zhang, B., Wang, Q., Zheng, S., Xia, Y., Zheng, Z., Lin, Z., Zhu, S., Zhang, X., Cui, L., Ying, H., Zhang, T., Zhou, S., Chen, Z., Lan, E., Zhang, Y., Lin, X., Chen, J., Qian, H., …, & Ma, Y. (2025). Comprehensive analysis of exosome-related gene signature in multiple myeloma prognosis and immune microenvironment evaluation. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-04097-x

Vancouver

Zheng D, Zhang B, Wang Q, Zheng S, Xia Y, Zheng Z, et al. Comprehensive analysis of exosome-related gene signature in multiple myeloma prognosis and immune microenvironment evaluation. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-04097-x

BibTeX
@article{Zheng2025,
  author = {Zheng, Dong and Zhang, Bingxin and Wang, Quanqiang and Zheng, Sisi and Xia, Yibo and Zheng, Ziwei and Lin, Zhili and Zhu, Shuxia and Zhang, Xinyi and Cui, Luning and Ying, Hansen and Zhang, Tianyu and Zhou, Shujuan and Chen, Zixing and Lan, Enqing and Zhang, Yu and Lin, Xuanru and Chen, Jingjing and Qian, Honglan and Hu, Xudong and Zhuang, Yan and Xie, Zuoting and Zhou, Xiangjing and Jin, Zhouxiang and Jiang, Songfu and Ma, Yongyong},
  title = {Comprehensive analysis of exosome-related gene signature in multiple myeloma prognosis and immune microenvironment evaluation},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  doi = {10.1007/s00262-025-04097-x}
}
Kostenlos starten →